Shin Nippon Biomedical Laboratories, Ltd. Stock BOERSE MUENCHEN
Equities
YB3
JP3379950003
Biotechnology & Medical Research
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
8 EUR | 0.00% | +1.27% | -25.93% |
Sales 2024 | 26.45B 169M 156M 231M | Sales 2025 * | 30.5B 195M 180M 267M | Capitalization | 55.41B 354M 327M 484M |
---|---|---|---|---|---|
Net income 2024 | 5.53B 35.32M 32.6M 48.34M | Net income 2025 * | 4.3B 27.46M 25.34M 37.58M | EV / Sales 2024 | 2.39 x |
Net Debt 2024 * | 19.51B 125M 115M 171M | Net Debt 2025 * | 22.77B 145M 134M 199M | EV / Sales 2025 * | 2.56 x |
P/E ratio 2024 |
11.4
x | P/E ratio 2025 * |
12.8
x | Employees | - |
Yield 2024 |
3.29% | Yield 2025 * |
3.79% | Free-Float | 48.8% |
1 week | +1.27% | ||
Current month | -10.61% | ||
1 month | -10.11% | ||
3 months | -20.79% | ||
6 months | -20.79% | ||
Current year | -25.93% |
Managers | Title | Age | Since |
---|---|---|---|
Ryoichi Nagata
CEO | Chief Executive Officer | 65 | 81-08-31 |
Shinji Nitanda
DFI | Director of Finance/CFO | 55 | 02-04-30 |
Terumasa Hirai
CMP | Compliance Officer | - | 84-03-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Ryoichi Nagata
CEO | Chief Executive Officer | 65 | 81-08-31 |
Ichiro Nagata
BRD | Director/Board Member | 38 | 17-03-31 |
Sales & Marketing | 64 | 02-10-31 |
Date | Price | Change |
---|---|---|
24-05-30 | 8 | 0.00% |
24-05-29 | 8 | 0.00% |
24-05-28 | 8 | +1.91% |
24-05-27 | 7.85 | 0.00% |
24-05-24 | 7.85 | -0.63% |
Real-time BOERSE MUENCHEN, May 30, 2024 at 09:13 am
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+48.67% | 56.69B | |
-2.76% | 41B | |
+39.41% | 38.11B | |
-11.22% | 26.89B | |
+9.25% | 25.59B | |
-23.10% | 18.59B | |
+1.88% | 12.39B | |
+26.43% | 11.99B | |
+21.74% | 11.88B |
- Stock Market
- Equities
- 2395 Stock
- YB3 Stock